Classification and definition of major flares in SLE clinical trials

Lupus

Volumn 8, Issue 8, 1999, Pages 685-691

  Petri, Michelle ^a   Buyon, Jill ^b   Kim, Mimi ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Disease activity; Flare; SLEDAI; Systemic lupus erythematosus

Indexed keywords

CLASSIFICATION; CLINICAL RESEARCH; DISEASE ACTIVITY; HUMAN; LONGITUDINAL STUDY; PREDICTION; PRIORITY JOURNAL; RELIABILITY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

CLINICAL TRIALS; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 0032752441     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399680411281     Document Type: Review

References (29)

1. Petri M, Barr SG, Zonana-Nach A, Magder L. Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort Experience. J Rheum 1999; 26: 502-503.
2. Glaman D, Ginzler E, Goldsmith C et al. Workshop Report. Systemic Lupus International Collaborative Clinics: development of a damage index in SLE. J Rheumatol 1992; 19: 1820-1821.
3. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992; 19: 53-59.
4. Hellmann DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: role of opportunistic organisms. Medicine 1987; 66: 341-348.
5. Bombardier C, Gladman DD, Urowitz M et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
6. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 1991; 34: 937-944.
7. Swaak AJG, Nossent JC, Bronsveld W et al. Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989; 48: 455-460.
8. Hay EM, Bacon PA, Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86(7): 447-458.
9. Stoll T, Stucki G, Malik J et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996; 55(10): 756-760.
10. Ehrenstein MR, Conroy SE, Heath J et al. The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol 1995; 34(3): 257-260.
11. Petri M, Magder L. Predictive value of anti-dsDNA for future SLE disease activity in patients who have had positive anti-dsDNA in the past [abstract]. Arthritis Rheum 1998; 41, (No. 9 Suppl): S217.
12. Esdaile JM, Abrahamowicz M, Joseph L et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus . Why some tests fail. Arthritis Rheum 1996; 39: 370-378.
13. Walz LeBlanc BAE, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus - predictors of clinical flares. J Rheumatol 1994; 21: 2239-2241.
14. ter Borg EJ, Horst G, Hummel EJ et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disese exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990; 33: 634-643.
15. Bootsma H, Spronk PE, ter Borg EJ et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 1997; 56: 661-666.
16. Spronk PE, Bootsma H, Kallenberg CG. Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Cuideline for treatment? Clin Rev Allergy Immunol 1998; 16: 211-218.
17. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional mesurements of complement. Arthritis Rheum 1992; 35: 1028-1037.
18. Kerr LD, Adelsberg BR, Schulman P, Spiera H. Factor B activation products in patients with systemic lupus erythematosus: a marker of severe disease activity. Arthritis Rheum 1985; 32: 1406-1413.
19. Fitzgerald JD, Grossman JM, Kalunian KC. Annual systemic lupus erythematosus flare rates in university practice [abstract]. Arthritis Rheum 1998; 41 (No. 9 Suppl): S219.
20. Dvorkina O, Aranow C, Orloff K et al. SLE disease activity an flare rates in premenopausal women in an urban center [abstract]. Arthritis Rheum 1998; 41 (No. 9 Suppl): S66.
21. Kagal A, Gladman D, Urowitz MB. Describing disease activity in SLE over time [abstract]. Arthritis Rheum 1998; 41 (No. 9 Suppl): S220.
22. Fortin PR, Ferland D, Moore AD et al. Rates and predictors of lupus flares. Arthritis Rheum 1998; 41 (No. 9 Suppl): S218.
23. Boumpas DT, Austin III HA, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
24. Gourley MF, Austin III HA, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125(7): 549-557.
25. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.
26. Petri M, Buyon J, Skovron ML, Kim M. Reliability of SELENA SLEDAI and flare as clinical trial outcome measures [abstract]. Arthritis Rheum 1997; 40 (No 9 Suppl): S218.
27. Kalunian KC, Buyon J, Merrill JT et al. Guidelines for use of the SLEDAI 1999; submitted.
28. Strand V, Gladman D, Isenberg D et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999; 26(2): 490-497.
29. Smolen JS, Strand V, Cardiel M et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999; 26(2): 504-507.